Ariane Laparra

Villejuif, 94805, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 37 publications

Macrophage CCL18 Promotes Lung Inflammation in Checkpoint Inhibitor Pneumonitis.

Macrophage CCL18 Promotes Lung Inflammation in Checkpoint Inhibitor Pneumonitis.

Journal: American journal of respiratory cell and molecular biology

Published: October 10, 2025

Concomitant Comedications and Survival With First-Line Pembrolizumab in Advanced Non-Small-Cell Lung Cancer.

Concomitant Comedications and Survival With First-Line Pembrolizumab in Advanced Non-Small-Cell Lung Cancer.

Journal: JAMA network open

Published: September 10, 2025

The toxicity pathway, an innovation for managing the toxicity of cancer treatments

The toxicity pathway, an innovation for managing the toxicity of cancer treatments

Journal: Soins; la revue de reference infirmiere

Published: September 07, 2025

Immune-related adverse events occurring rapidly after a single dose of immune checkpoint blockade.

Immune-related adverse events occurring rapidly after a single dose of immune checkpoint blockade.

Journal: Journal for immunotherapy of cancer

Published: August 25, 2025

Plasma exchange as potential treatment of severe immune checkpoint inhibitor-induced hepatitis.

Plasma exchange as potential treatment of severe immune checkpoint inhibitor-induced hepatitis.

Journal: JHEP reports : innovation in hepatology

Published: August 09, 2025

Macrophage CCL18 promotes lung inflammation in checkpoint inhibitor pneumonitis.

Macrophage CCL18 promotes lung inflammation in checkpoint inhibitor pneumonitis.

Journal: American journal of respiratory cell and molecular biology

Published: July 08, 2025

From toxicity assessment to adaptive safety care: implementing comprehensive fast-track safety evaluation for anticancer drug development.

From toxicity assessment to adaptive safety care: implementing comprehensive fast-track safety evaluation for anticancer drug development.

Journal: ESMO open

Published: May 02, 2025

Infectious Complications in Patients Treated With T-cell Engagers as Cancer Immunotherapies, a Descriptive Study From the REISAMIC Registry.

Infectious Complications in Patients Treated With T-cell Engagers as Cancer Immunotherapies, a Descriptive Study From the REISAMIC Registry.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Published: February 21, 2025

Immuno-oncology in the daily practice.

Immuno-oncology in the daily practice.

Journal: Current opinion in oncology

Published: January 27, 2025

Immune checkpoint inhibitors-induced large vessel vasculitis: clinical characteristics and management from a European multicentre study.

Immune checkpoint inhibitors-induced large vessel vasculitis: clinical characteristics and management from a European multicentre study.

Journal: Rheumatology (Oxford, England)

Published: January 24, 2025

Real-world safety and effectiveness of neoadjuvant chemotherapy combination with pembrolizumab in triple-negative breast cancer.

Real-world safety and effectiveness of neoadjuvant chemotherapy combination with pembrolizumab in triple-negative breast cancer.

Journal: ESMO real world data and digital oncology

Published: August 08, 2024

Acute kidney injury in cancer patients receiving immune checkpoint inhibitor therapy-shared guidelines of FITC/SFNDT

Acute kidney injury in cancer patients receiving immune checkpoint inhibitor therapy-shared guidelines of FITC/SFNDT

Journal: Bulletin du cancer

Published: June 28, 2024

Showing 1-12 of 37

Last Updated: 09/26/2026